ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Mortality rates in congestive heart failure (CHF) are still increasing, but leading cardiologists believe there is cause for optimism in the light of recent trial results. For a while, it seemed that triple therapy with digoxin, diuretics and an ACE inhibitor could not be improved upon. But now, studies of &bgr;-blockers, calcium antagonists and an aldosterone inhibitor have shown that these agents may provide additional benefit to certain patients. These studies were discussed at the 44th Annual Scientific Sessions of the American College of Cardiology [New Orleans, US; March 1995]. No definitive conclusions have yet been drawn, but the groundwork has been laid for a new era of heart failure research.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Researchers are now suggesting that antisense oligonucleotides may inhibit cell growth in acute and chronic myelogenous leukaemia (AML and CML). Encouraging results have been achieved with a phosphorothioate-modifiedc-mybantisense oligonucleotide used as a bone marrow purging agent in patients with CML. In addition, the antisense oligonucleotide OL(1)p53 inhibited the growth of human AML blast cellsin vitro, and has now been administered to patients with AML or myelodysplastic syndrome (MDS). The latest progress with these agents, being developed in affiliation with Lynx Therapeutics, was discussed at the IIR Ltd conference, entitled‘Antisense Therapy: Efficacy and Delivery of Antisense & Ribozyme Oligonucleotides’[London, UK; February 1995].

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS